RNAi News and Research

RSS

Scientists identify dozens of proteins the dengue fever virus depends upon

By painstakingly silencing genes one at a time, scientists at Duke University Medical Center have identified dozens of proteins the dengue fever virus depends upon to grow and spread among mosquitoes and humans.

22 Apr 2009

New Dengue virus discovery could lead to development of anti-dengue drugs

Doctors have no specific drugs to treat dengue fever, a viral illness spread by mosquitoes that sickens 50 million to 100 million people worldwide each year. Instead, the only treatments they can recommend for this painful and sometimes fatal illness (20,000 deaths globally each year) are fluids, rest and non-aspirin pain and fever reducers.

22 Apr 2009

Discovery of key decision-point at which cells with broken DNA repair themselves or die

When cells undergo potentially catastrophic damage, for example as a result of exposure to ionizing radiation, they must make a decision: either to fix the damage or program themselves for death, a process called apoptosis.

12 Apr 2009

Researchers explain process by which cells 'hide' potentially dangerous DNA segments

The DNA in the 23 pairs of chromosomes in each of the billions of cells of the human body is so tightly packed that it would measure six feet in length if stretched end to end.

12 Apr 2009

Intradigm receives notice of allowance for key RNA interference patent covering potent siRNA sequence

Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, has announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance for a patent covering various aspects of a potent small interfering RNA (siRNA) sequence.

17 Mar 2009

Protein function and chromatin structure methods featured in Cold Spring Harbor Protocols

Two new methods for analyzing the roles played by proteins in cells are featured in the March issue of Cold Spring Harbor Protocols.

3 Mar 2009

Novel gene silencing platform

A team of researchers led by Rutgers' Samuel Gunderson has developed a novel gene silencing platform with very significant improvements over existing RNAi approaches.

16 Feb 2009

Novel gene silencing platform

A team of researchers led by Rutgers' Samuel Gunderson has developed a novel gene silencing platform with very significant improvements over existing RNAi approaches.

8 Feb 2009

Topical treatment wipes out herpes with RNAi

Whether condoms or abstinence, most efforts to prevent sexually transmitted diseases have a common logic: keep the pathogen out of your body altogether.

21 Jan 2009

Topical microbicide protects against genital herpes

A topical microbicide that silences two genes can safely protect against genital herpes infection for as long as one week, according to a joint study by researchers at the Albert Einstein College of Medicine of Yeshiva University and Harvard Medical School.

21 Jan 2009

Liquidia Technologies to collaborate with Abbott on siRNA therapeutics

Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.

7 Jan 2009

Blocking mechanism found for antibiotic resistance in bacteria

It's as simple as A, T, G, C. Northwestern University scientists have exploited the Watson-Crick base pairing of DNA to provide a defensive tool that could be used to fight the spread of antibiotic resistance in bacteria -- one of the world's most pressing public health problems.

18 Dec 2008

Researchers stop ovarian cancer cell cycle in its tracks

Ovarian cancer cells are "addicted" to a family of proteins produced by the notorious oncogene, MYC, and blocking these Myc proteins halts cell proliferation in the deadliest cancer of the female reproductive system, according to a presentation by University of California, Berkeley scientists at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.

15 Dec 2008

Blocking Myc proteins stops ovarian cancer cell cycle in its tracks

Ovarian cancer cells are "addicted" to a family of proteins produced by the notorious oncogene, MYC.

15 Dec 2008

RNA interference can facilitate vaccine development

Pharmaceutical companies and universities are racing to develop drugs that use the gene silencing mechanism known as RNA interference to treat a host of diseases.

10 Dec 2008

Researchers map changing epigenetic modifications that enable transposons to run amok

Cold Spring Harbor, N.Y. – Much like cancer cells, plant cells grown for a long time outside of their normal milieu, in culture dishes, have highly unstable genomes.

10 Dec 2008

Alnylam Pharmaceuticals update on Kreutzer-Limmer patent estate

Alnylam Pharmaceuticals, Inc. has announced that the European Patent Office (EPO) has ruled in favor of the Appellants in oral proceedings before the Board of Appeals related to the '623 (EP 1144623) patent in its Kreutzer-Limmer patent estate.

10 Dec 2008

Breakthrough in understanding the phenomenon of nucleolar dominance

Since the machinery involved in nucleolar dominance is some of the same machinery that can go haywire in diseases such as cancer, Pikaard and his collaborators' research may have important implications for applied medical research.

5 Dec 2008

Discovery of groundbreaking technique for body to accept gene therapy

Researchers at Columbia University Medical Center and the State University of New York at Stony Brook (SUNY) have developed a groundbreaking technique to sneak therapeutic genes past the body's defenses, possibly clearing one of the largest hurdles to realizing the potentials of medically altering a patient's DNA.

5 Dec 2008

Intradigm issued new RNAi therapeutics patent

Intradigm Corporation has announced the issuance of United States patent 7,459,547, entitled "Methods and Compositions for Controlling Efficacy of RNA Silencing."

3 Dec 2008